| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Iminostilbene does not have a defined pharmacological target. As a metabolite of carbamazepine, it may contribute to the pharmacological effects or side effects of the parent drug. It has been shown to target pyruvate kinase and COX.
|
|---|---|
| ln Vitro |
In vitro, iminostilbene is used as a reference standard and as a building block for the synthesis of other compounds. It may be used to study the metabolism of carbamazepine. No specific pharmacological activities have been reported for the compound itself.
|
| ln Vivo |
In vivo, iminostilbene is a metabolite of carbamazepine. It is formed by the metabolism of carbamazepine in the liver. Its levels in the body can be used to monitor carbamazepine metabolism.
|
| Enzyme Assay |
Non-cellular assays for iminostilbene involve its characterization using analytical methods such as HPLC and mass spectrometry. It can be used as a standard in these assays.
|
| Cell Assay |
Cell-based assays are not typically performed with iminostilbene as a test article.
|
| Animal Protocol |
In vivo animal studies with iminostilbene are not typically conducted, as it is a metabolite.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for iminostilbene are related to the metabolism of carbamazepine. It is formed and eliminated as part of carbamazepine's metabolic pathway.
|
| Toxicity/Toxicokinetics |
Iminostilbene may cause irritation. Standard laboratory safety precautions should be followed.
|
| References |
[1]. Christian P, et al. Crystallization of Carbamazepine in Proximity to Its Precursor Iminostilbene and a Silica Surface. Cryst Growth Des. 2016 May 4;16(5):2771-2778. Epub 2016 Mar 30.
|
| Additional Infomation |
5H-Dibenzo[b,f]azapyrrolidone is a nitrogen-containing organic heterotricyclic parent compound, consisting of a seven-membered nitrogen-containing heterocycle fused with two benzene rings. It is a marine xenobiotic metabolite. It is both a nitrogen-containing organic heterotricyclic parent compound and a dibenzo[b,f]azapyrrolidone.
Iminostilbene is a research chemical and a pharmaceutical intermediate. It is used for the production of carbamazepine and oxcarbazepine. It is not an approved drug. |
| Molecular Formula |
C14H11N
|
|---|---|
| Molecular Weight |
193.25
|
| Exact Mass |
193.089
|
| CAS # |
256-96-2
|
| Related CAS # |
Iminostilbene-d4
|
| PubChem CID |
9212
|
| Appearance |
Yellow to orange solid powder
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
349.1±22.0 °C at 760 mmHg
|
| Melting Point |
197 °C
|
| Flash Point |
178.4±17.8 °C
|
| Vapour Pressure |
0.0±0.8 mmHg at 25°C
|
| Index of Refraction |
1.627
|
| LogP |
4.11
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
15
|
| Complexity |
222
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
N1([H])C2=C([H])C([H])=C([H])C([H])=C2C([H])=C([H])C2=C([H])C([H])=C([H])C([H])=C12
|
| InChi Key |
LCGTWRLJTMHIQZ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C14H11N/c1-3-7-13-11(5-1)9-10-12-6-2-4-8-14(12)15-13/h1-10,15H
|
| Chemical Name |
11H-benzo[b][1]benzazepine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 50 mg/mL (258.73 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (12.94 mM) (saturation unknown) in 10% DMSO + 40% PEG300 +5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 + to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.1746 mL | 25.8732 mL | 51.7464 mL | |
| 5 mM | 1.0349 mL | 5.1746 mL | 10.3493 mL | |
| 10 mM | 0.5175 mL | 2.5873 mL | 5.1746 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
